DK0639079T3 - Methods for the treatment of interleukin-1 and tumor necrosis factor-mediated diseases - Google Patents

Methods for the treatment of interleukin-1 and tumor necrosis factor-mediated diseases

Info

Publication number
DK0639079T3
DK0639079T3 DK93910992T DK93910992T DK0639079T3 DK 0639079 T3 DK0639079 T3 DK 0639079T3 DK 93910992 T DK93910992 T DK 93910992T DK 93910992 T DK93910992 T DK 93910992T DK 0639079 T3 DK0639079 T3 DK 0639079T3
Authority
DK
Denmark
Prior art keywords
inhibitor
methods
mediated diseases
tnf
interleukin
Prior art date
Application number
DK93910992T
Other languages
Danish (da)
Inventor
Robert C Thompson
Deborah A Russell
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of DK0639079T3 publication Critical patent/DK0639079T3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)

Abstract

The invention relates to methods for treating or preventing diseases that are IL-1 mediated diseases or TNF mediated diseases, including arthritis, septic shock, inflammatory bowel disease, ischemia injury, reperfusion injury, pulmonary fibrosis and adult respiratory distress syndrome. The method comprises administering to patients in need thereof therapeutically effective amounts of an IL-1 inhibitor and a TNF inhibitor. In a preferred embodiment, the IL-1 inhibitor is human recombinant IL-1ra and the TNF inhibitor is human recombinant 30kDa TNF inhibitor. The invention also relates to pharmaceutical compositions containing an IL-1 inhibitor and a TNF inhibitor useful in such methods.
DK93910992T 1992-04-30 1993-04-28 Methods for the treatment of interleukin-1 and tumor necrosis factor-mediated diseases DK0639079T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87634492A 1992-04-30 1992-04-30
PCT/US1993/004141 WO1993021946A1 (en) 1992-04-30 1993-04-28 Methods for treating interleukin-1 and tumor necrosis factor mediated diseases

Publications (1)

Publication Number Publication Date
DK0639079T3 true DK0639079T3 (en) 2000-06-13

Family

ID=25367492

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93910992T DK0639079T3 (en) 1992-04-30 1993-04-28 Methods for the treatment of interleukin-1 and tumor necrosis factor-mediated diseases

Country Status (11)

Country Link
EP (1) EP0639079B1 (en)
JP (2) JPH07509223A (en)
AT (1) ATE188610T1 (en)
AU (1) AU672606B2 (en)
CA (1) CA2118119C (en)
DE (1) DE69327582T2 (en)
DK (1) DK0639079T3 (en)
ES (1) ES2142341T3 (en)
GR (1) GR3033144T3 (en)
PT (1) PT639079E (en)
WO (1) WO1993021946A1 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858409B1 (en) 1988-05-27 2005-02-22 Amgen Inc. Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US6159460A (en) * 1988-05-27 2000-12-12 Amgen Inc. Method for treating interleukin-1 mediated diseases
CA2139385C (en) * 1994-02-04 2001-12-25 Gottfried Alber Products containing g-csf and tnf binding protein
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
US7005413B1 (en) 1995-12-22 2006-02-28 Amgen Inc. Combination therapy for conditions leading to bone loss
ATE406176T1 (en) 1996-12-06 2008-09-15 Amgen Inc IL-1 INHIBITOR IN COMBINATION THERAPY FOR THE TREATMENT OF IL-1-MEDIATED DISEASES
DE69740107D1 (en) 1996-12-23 2011-03-10 Immunex Corp RECEPTOR ACTIVATOR OF NF-KAPPA B, RECEPTOR IS A MEMBER OF THE TNF RECEPTOR SUPERFAMILY
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
PT911342E (en) 1997-04-15 2006-08-31 Sankyo Co NEW PROTEIN AND PROCESS TO PRODUCE
SK288559B6 (en) 1997-04-16 2018-05-02 Amgen, Inc. Nucleic acid, polypeptide, expression vector and host cell; osteoprotegerin binding protein and process for its preparation, antibody and medicament for preventing or treating bone diseases
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
US6013253A (en) * 1997-08-15 2000-01-11 Amgen, Inc. Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
JP4454859B2 (en) 1998-11-13 2010-04-21 イミュネックス・コーポレーション Human TSLP DNA and polypeptides
IL145714A0 (en) * 1999-04-02 2002-07-25 Interleukin Genetics Inc Prediction of risk of interstitial lung disease
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
AU6078500A (en) * 1999-07-09 2001-01-30 Amgen, Inc. Combination therapy for conditions leading to bone loss
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
EP1282435A2 (en) * 2000-05-12 2003-02-12 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
EP2087908B1 (en) 2001-06-26 2018-05-30 Amgen Inc. Antibodies to opgl
US7288633B2 (en) 2001-07-23 2007-10-30 Immunex Corporation Modified human thymic stromal lymphopoietin
WO2003086289A2 (en) 2002-04-05 2003-10-23 Amgen Inc. Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
CA2497884C (en) 2002-09-06 2013-10-22 Brian Varnum Therapeutic human anti-il-1r1 monoclonal antibody
CA2577631A1 (en) * 2004-08-20 2006-03-02 Amgen Inc. Methods and compositions for treating allergic inflammation
US7795385B2 (en) * 2004-12-17 2010-09-14 Bexar Global, Inc. Use of bombesin/gastrin-releasing peptide antagonists for the treatment of inflammatory conditions, acute lung injury and bipolar disorder
PE20070684A1 (en) 2005-11-14 2007-08-06 Amgen Inc RANKL-PTH / PTHrP ANTIBODY CHEMERICAL MOLECULES
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
US9383348B2 (en) 2008-06-21 2016-07-05 John E. Repine Compositions and methods for treating lung disorders
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
CN102574907B (en) * 2009-10-19 2015-10-21 韩诺生物制药株式会社 The human tumor necrosis factor receptor I polypeptide of modifying or its fragment and prepare their method
WO2011088120A1 (en) 2010-01-15 2011-07-21 Amgen Inc. Antibody formulation and therapeutic regimens
US20140234330A1 (en) 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
US20170174772A1 (en) 2014-03-31 2017-06-22 Kirin-Amgen, Inc. Methods of treating nail and scalp psoriasis
WO2015191783A2 (en) 2014-06-10 2015-12-17 Abbvie Inc. Biomarkers for inflammatory disease and methods of using same
US10041044B2 (en) 2016-07-29 2018-08-07 Trustees Of Boston University Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development
WO2020035482A1 (en) 2018-08-13 2020-02-20 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
WO2023222565A1 (en) 2022-05-16 2023-11-23 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0148009B1 (en) * 1988-05-27 1998-08-01 그래고리 비. 아보트 Interleukin-1 inhibitors
IL95031A (en) * 1989-07-18 2007-03-08 Amgen Inc Method for the production of a human recombinant tumor necrosis factor inhibitor
US5395760A (en) * 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
JPH0357034U (en) * 1989-10-11 1991-05-31
DE69230789T3 (en) * 1991-01-18 2007-10-31 Amgen Inc., Thousand Oaks METHODS OF TREATING ILLNESSES RELEASED BY THE TUMOR NEKROSE FACTOR

Also Published As

Publication number Publication date
JPH07509223A (en) 1995-10-12
PT639079E (en) 2000-04-28
CA2118119C (en) 2001-07-31
DE69327582D1 (en) 2000-02-17
DE69327582T2 (en) 2000-08-03
WO1993021946A1 (en) 1993-11-11
JP2002220342A (en) 2002-08-09
EP0639079B1 (en) 2000-01-12
AU4229493A (en) 1993-11-29
ATE188610T1 (en) 2000-01-15
AU672606B2 (en) 1996-10-10
CA2118119A1 (en) 1993-11-11
GR3033144T3 (en) 2000-08-31
ES2142341T3 (en) 2000-04-16
EP0639079A1 (en) 1995-02-22

Similar Documents

Publication Publication Date Title
DK0639079T3 (en) Methods for the treatment of interleukin-1 and tumor necrosis factor-mediated diseases
DE69738948D1 (en) IL-1 inhibitor in combination therapy for the treatment of IL-1 mediated diseases
DK0713701T3 (en) 2-Bromelatonin for the treatment of sleep disorders
DK0567566T3 (en) Methods for the treatment of tumor necrosis factor-mediated diseases
NO943901D0 (en) Methods and Preparations for the Treatment of Diseases with Interferon While Reducing Side Effects
EA200100872A1 (en) COMPOSITION VALDEKOKSIBA
DE69334317D1 (en) Purified DNAse forms
DE59007288D1 (en) Use of the active ingredient azelastine and glycerin ethers to combat psoriasis diseases.
DE69733089D1 (en) Treatment of osteotarthritis by administration of poly-N-acetyl-D-glucosamine
ATE481135T1 (en) COMBINATION THERAPY WITH OMEGA INTERFERON FOR THE TREATMENT OF HEPATITIS C VIRUS OR YELLOW FEVER VIRUS INFECTIONS
ATE82294T1 (en) THERAPEUTIC NUCLEOSIDES.
NO931413D0 (en) METHODS AND PREPARATIONS FOR TREATMENT OF CELL PROLIFERATION DISEASES
DK347289A (en) THERAPEUTIC RELATIONS
RU2003100517A (en) NEW INTERFERON FOR THE TREATMENT OF MULTIPLE SCLEROSIS
NO971453D0 (en) Use of bradykinin antagonists in the manufacture of drugs for the treatment of chronic fibrogenetic and acute liver diseases
JP2752250B2 (en) Basic therapeutic agent with analgesic and anti-inflammatory action
LV12308A (en) Compositions containing isothiazole derivatives and bioactive products are released from the tissue
DE69118847D1 (en) Use of heptastigmine to treat cerebral icus
RU93004467A (en) SUBSTITUTED PURIN ARABINOSES, THEIR APPLICATION, PHARMACEUTICAL COMPOSITION
RU93008990A (en) METHOD FOR TREATMENT AND PREVENTION OF ACUTE ENDOMETRITIS IN COWS
TH13285EX (en) Compounds used to treat degenerative diseases
RU93035856A (en) METHOD OF TREATMENT OF OBLITERATED ENDARTERIITIS